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Interferon regulatory factor 9 (IRF9), as interferon-stimulated
gene factor 3 gamma (ISGF3G), belongs to the IRF family and
participates in a series of molecular pathways related to cell pro-
liferation, oncogenesis, apoptosis, and innate immunity. IRF9 not
only acts as a transcription factor, but also interacts with other
transcription factors to regulate gene expression. However, IRF9
has a dual role in health and disease. Recently, the article by
Wang et al. [1] showed that IRF9 overexpression aggravated the
hepatic ischemia/reperfusion (I/R) injury and its deﬁciency sig-
niﬁcantly mitigated the symptoms after liver I/R. The results
demonstrated that IRF9 induced hepatocyte apoptosis after I/R
injury. Moreover, the paper by Zhang et al. [2] indicated that
IRF9 deletion suppressed the proliferation and migration of
vascular smooth muscle cells (VSMC) and ameliorated intimal
thickening. In contrast, IRF9 gain-of-function promoted VSMC
proliferation and migration and aggravated arterial narrowing.
Furthermore, the article by Chen et al. [3] showed that IRF9
accumulated in neurons in response to I/R and IRF9 deﬁciency
markedly attenuated both post-stroke neuronal death and
neurological deﬁcits. By comparison, IRF9 overexpression in
neurons resulted in affected neurons to die. In addition, Zhang
et al. [4] indicated that IRF9 upregulation was found in human
ischemic heart tissue and mouse hearts after I/R injury.
Furthermore, IRF9 deﬁciency protected the heart against
I/R-induced cardiomyocyte death, inﬂammation, and dysfunc-
tion. Whereas, IRF9 overexpression in cardiomyocyte aggravated
myocardial reperfusion injury and inﬂammation.
From the above data, IRF9 was suggested as a negative reg-
ulator in the suppression of I/R injury, arterial narrowing, post-
stroke neuronal death and neurological deﬁcits. However, the
article by Jiang et al. [5] showed that IRF9 deﬁciency presented
marked cardiac hypertrophy and IRF9 overexpression exhibited
the decrease of hypertrophic response. The results demonstrated
that IRF9 suppressed the development of cardiac hypertrophy. It
indicated that IRF9 played a positive role in the inhibition of car-
diac hypertrophy.
Together, these ﬁndings suggested that IRF9 not only acted as
a negative regulator, but also a suppressor in health and disease,
such as I/R injury, arterial narrowing, post-stroke neuronal death
and neurological deﬁcits, and cardiac hypertrophy. We read withJournal of Hepatology 2015
er CC BY-NC-ND license.interest the article by Wang et al. and thought that IRF9 may play
a dual function in health and disease.
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